Moreover, concomitant targeting of other host proteins with key roles in cell survival, such as the cellular inhibitor of apoptosis protein 2 (cIAP2) that has been involved in HBV-induced sorafenib resistance in liver cancer cells [81], may result in synergistic or potentiation effects and thus increase efficacy of cancer treatment. This evidence concerns the gene BIRC3 and cancer.